Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

FTSE 250 Hikma Pharmaceuticals (LSE:HIK): The appointment of umang vohra as a director against the backdrop of improved 2026 operating guidance puts shares in focus today

• Hikma recently narrowed its expected 2026 Group operating-profit range to $740 million-$760 million. Branded has been outperforming, Hikma Rx profitability has been improving and Injectables has been stabilising, while management continues to invest in launches and R&D.

Ankur Sharma | 09 November 2026

How Hikma (LSE:HIK) is bringing former Cipla chief Umang Vohra onto its board

• Vohra will also join Hikma's Audit Committee and its Nomination and Governance Committee on appointment.

Ankur Sharma | 09 November 2026

NIOX Group plc (LSE:NIOX) FTSE AIM 100 Tender Completion Puts FeNO Growth and Remaining Cash Capacity in Focus

Investors should watch consumables demand, device placement, regional sales, product development and cash generation after the tender.

Ankur Sharma | 09 November 2026

ImmuPharma plc (LSE:IMM) FTSE AIM All-Share P140 and Kapiglucagon Put Development Milestones Ahead of Market Hype

Investors should watch study initiation, regulatory submissions, clinical data,Partnershipterms and cash commitments across the development portfolio.

Ankur Sharma | 09 November 2026

How Abingdon Health (LSE:ABDX) Narrowed Its Loss in a Year Watched on the FTSE AIM All Share Index

Cash and equivalents increased to £2.9 million, helped by £3.2 million ofEquityraised during the year. The company said it expects continued revenue growth and an improved EBITDA position in the 2027 financial year, but noted that short-term delays affected the first quarter of the …

Ishan Mudgal | 06 November 2026

What the Takeover Disclosures Mean for Advanced Medical Solutions (LSE:AMS) on the FTSE AIM All Share Index

The Rule 2.9 announcement, published at 1:42 p.m. on 4 November, stated that the company had 221,042,797 ordinary shares of 5p each in issue and admitted to trading on AIM, with none held in treasury, so all carry voting rights. The summary of the …

Ishan Mudgal | 06 November 2026

How AOTI (LSE:AOTI) Could Gain From Medicare Coverage as a FTSE AIM All Share Index Medtech Name

For the first half of 2026, underlying revenue, which excludes Arizona Medicaid, rose 18.8% to $31.9 million. Reported revenue increased 10.8% to $35.3 million. EBITDA grew 16.6% to $3.6 million, andOperating Cash Flowwas positive at $0.9 million, a marked improvement on the outflow of …

Ishan Mudgal | 06 November 2026

Why Aptamer Group (LSE:APTA) Calls 2026 a Year of Inflection on the FTSE AIM All Share Index

Founded in 2008, Aptamer develops Optimer binders, synthetic alternatives to antibodies for life sciences, diagnostic and therapeutic uses. It earns fee-for-service research revenue and builds proprietaryAssetsthat it can license for royalties and supply.

Ishan Mudgal | 06 November 2026

Why Arecor (LSE:AREC) Went to Market for £5.13m: A FTSE AIM All Share Index Biotech Update

According to a summary of the interim results,Revenuewas £0.2m against £1.0m a year earlier,Research and Developmentcosts rose to £1.9m from £1.3m, and the loss after tax widened to £3.0m from £2.0m. Cash was £3.2m, up from £1.9m. The figures come from an AI-generated summary …

Ishan Mudgal | 06 November 2026

Sareum Holdings plc (SAR) Under the Microscope: Latest Developments and the Next Investor Triggers

• Sector conditions can amplify moves in smaller UK-listed shares.

Ankur Sharma | 06 November 2026
Support

Hi! How can we help you today?

Loading…